Edition:
United States

Achillion Pharmaceuticals Inc (ACHN.O)

ACHN.O on Nasdaq

3.36USD
22 Nov 2017
Change (% chg)

$-0.07 (-2.04%)
Prev Close
$3.43
Open
$3.45
Day's High
$3.54
Day's Low
$3.34
Volume
1,387,738
Avg. Vol
1,910,528
52-wk High
$5.66
52-wk Low
$2.95

Latest Key Developments (Source: Significant Developments)

Achillion Pharmaceuticals Q4 revenue $15 million
Thursday, 23 Feb 2017 04:05pm EST 

Achillion Pharmaceuticals Inc : Achillion reports 2016 fourth quarter and year-end financial results . Sees FY 2017 loss per share $0.70 to $0.75 . Q4 revenue $15 million . Q4 revenue view $0 -- Thomson Reuters I/B/E/S . Expects that research and development expenses during 2017 will be approximately $75 - 80 million . Net cash used in operating activities in 2017 will be approximately $70 - 75 million .FY2017 earnings per share view $-0.40 -- Thomson Reuters I/B/E/S.  Full Article

Achillion Pharmaceuticals reports Q2 loss per share $0.14
Thursday, 4 Aug 2016 04:05pm EDT 

Achillion Pharmaceuticals Inc : Achillion reports second quarter 2016 financial results .Achillion Pharmaceuticals Inc qtrly loss per share $0.14.  Full Article

Achillion presents interim phase 1 results for ACH-4471
Friday, 10 Jun 2016 03:30am EDT 

Achillion says : Presents interim phase 1 results for ACH-4471, a novel orally-administered factor D inhibitor . Results indicate up to 100% inhibition of alternative-pathway activity in hemolysis and Wieslab assays after oral dosing of ACH-447 .Results support initiation of phase 1 trial during q2 and phase 2 studies for PNH and C3G by year-end 2016.  Full Article